R&D channel feed – Endpoints News

R&D channel feed

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial

5 months ago

Biohaven's myostatin inhibitor misses primary endpoint in spinal muscular atrophy trial

5 months ago

AstraZeneca’s Truqap edges closer to prostate cancer label expansion with Phase 3 win

5 months ago

Patient dies in Neurogene's Rett syndrome study

5 months ago

AstraZeneca culls Phase 2 opioid use disorder drug

5 months ago

Caltech spinout debuts with AI-driven 'mirror peptide' platform

5 months ago

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

5 months ago

NewAmsterdam aces Phase 3 trial, but investors are skeptical

5 months ago

Novo and Viking present new MASH data, but analysts remain confident in Madrigal's Rezdiffra

5 months ago

Updated: Sage reports Phase 2 failure in Huntington's disease, ends drug's development

5 months ago

Lilly’s oral cardio drug that blocks lipids passes mid-stage test

5 months ago

J&J, Protagonist reveal two Phase 3 wins for oral IL-23 drug that's expected to be a blockbuster

5 months ago

Bristol Myers takes on autoimmune diseases with cell therapy, plus new data from Cabaletta and Kyverna

5 months ago

Merck finally has subcutaneous Keytruda results, and it's going to regulators

5 months ago

Incyte’s bet on Escient hits a snag as safety issues hamper Phase 2 chronic hives trial

5 months ago

Biogen, UCB detail response rates in Phase 3 lupus trial after surprising success

5 months ago

Vir, Bluejay invigorate hepatitis D space with new data

5 months ago

Rocket shares promising long-term results from rare heart disease gene therapy in small study

5 months ago

Neurogene patient had life-threatening side effect in Rett syndrome study

5 months ago

Regenxbio shares first data showing Duchenne gene therapy improves muscle function

5 months ago

A rare neurological disease is Sage’s last, best hope after failures in depression

5 months ago

As cardiomyopathy market expands, Alnylam offers look at Phase 1 data in healthy volunteers

5 months ago

Cybin says its psychedelic drug can sustain remission in depression patients

5 months ago

Intellia touts first clinical outcomes on CRISPR-based ATTR amyloidosis asset

5 months ago

First page Previous page 15 16 171819 20 21 Next page Last page